You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

132 search results for: patient burden

expert video

The Path to Nodules: Type 2 Inflammation at the Core of Chronic Itch and Fibrosis in Prurigo Nodularis

11 min

Type 2 Inflammation

Join Dr. Shawn Kwatra in discussing the diverse clinical presentations of PN and the role of type 2 inflammation in disease pathogenesis.

From Endotype to Phenotype: Linking Pathophysiology to <b>Burden</b> and Clinical Management for <b>Patient</b>s with Uncontrolled and/or Severe CRSwNP

expert video

From Endotype to Phenotype: Linking Pathophysiology to Burden and Clinical Management for Patients with Uncontrolled and/or Severe CRSwNP

9 min

Rhinology

Prof. Peter Hellings discusses the interconnection between the pathophysiology, burden and clinical management of uncontrolled and/or severe CRSwNP.

ERS 2024 | Living With COPD: Linking Inflammation with <b>Patient</b> <b>Burden</b>

expert video

ERS 2024 | Living With COPD: Linking Inflammation with Patient Burden

15 min

Pulmonology

Professor Henrik Watz explores the complex relationship between inflammation and COPD, highlighting its impact on patients' health and overall quality of life.

Prurigo Nodularis: The <b>Patient</b> Journey

interactivity

Prurigo Nodularis: The Patient Journey

5 min

Dermatology

An interactive tool highlighting the disease burden, impact and management of prurigo nodularis throughout the patient journey before diagnosis, during diagnosis and during treatment.

expert video

Inside the Hive: Type 2 Inflammatory Pathways in Chronic Spontaneous Urticaria

16 min

Dermatology

Join Dr. Jason Hawkes in discussing the burden of CSU and how type 2 inflammation contributes to the development of chronic wheals (hives) and angioedema

The Prevalence and <b>Burden</b> of Type 2 Inflammation in <b>Patient</b>s With CRSwNP

expert video

The Prevalence and Burden of Type 2 Inflammation in Patients With CRSwNP

8 min

Rhinology

Dr. Stella Lee educates on the immune responses mediating CRSwNP and the prevalence of type 2 inflammation.

Why Is It Important to Assess Lung Function in Pediatric Severe Asthma <b>Patient</b>s?

expert video

Why Is It Important to Assess Lung Function in Pediatric Severe Asthma Patients?

18 min

Pulmonology

Prof. Monika Gappa presents the importance in assessment of lung function in pediatric patients alongside the associated patient burden.

IRS-ISIAN 2024 | The Underappreciated <b>Burden</b> of Smell Loss and Congestion in CRSwNP

expert video

IRS-ISIAN 2024 | The Underappreciated Burden of Smell Loss and Congestion in CRSwNP

7 min

Rhinology

Prof. Joaquim Mullol describes the burdens of smell loss and nasal congestion for patients with uncontrolled and/or severe CRSwNP.

Trajectories of Type 2 Inflammation in Pediatric <b>Patient</b>s

expert video

Trajectories of Type 2 Inflammation in Pediatric Patients

43 min

Type 2 Inflammation

Drs. Jonathan Spergel, Wanda Phipatanakul, Eric Simpson, Prof. Salvatore Oliva discuss pediatric patient/caregiver burden and multidisciplinary care

expert video

EAACI 2023 | Pediatric Type 2 Inflammatory Disease Progression

40 min

Type 2 Inflammation

Dr. Leonard Bacharier and Profs. Oscar Palomares and Stephan Weidinger explore shared features of type 2 pathophysiology in AD, asthma, and EoE, and disease burden in pediatric patients

Emerging Therapeutic Landscape and Implications for <b>Patient</b> Management in CSU

expert video

Emerging Therapeutic Landscape and Implications for Patient Management in CSU

24 min

Dermatology

A review of disease burden and treatment needs in CSU, and how current and emerging therapies can impact patient management.

Updates in PN and CSU: Emerging Therapeutic Landscapes and Implications for <b>Patient</b> Management

expert video

Updates in PN and CSU: Emerging Therapeutic Landscapes and Implications for Patient Management

49 min

Dermatology

A review of disease burden and treatment needs in PN and CSU, and how current and emerging therapies can impact patient management in these respective diseases.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: SudanChange country/region